{
    "clinical_study": {
        "@rank": "141324", 
        "arm_group": {
            "arm_group_label": "Candesartan cilexetil / hydrochlorothiazide", 
            "description": "Candesartan cilexetil / hydrochlorothiazide combination tablets LD&HD"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy  of long-term use of candesartan cilexetil /\n      hydrochlorothiazide combination tablets (ECARD) Combination Tablets LD&HD in hypertensive\n      patients in the routine clinical setting"
        }, 
        "brief_title": "Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of candesartan cilexetil /\n      hydrochlorothiazide combination tablets (ECARD combination tablets) to evaluate  in\n      hypertensive patients  in the routine clinical setting. Because the drug contains a diuretic\n      (hydrochlorothiazide) , it is necessary to assess the safety,especially on serum uric acid.\n      (the planned sample size is 3000).\n\n      The usual adult dosage is 1 tablet (4 mg/6.25 mg or 8 mg/6.25 mg as a candesartan\n      cilexetil/hydrochlorothiazide) administered orally once daily. This drug should not be used\n      as a first-line drug for hypertension treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hypertensive patients\n\n        Exclusion Criteria:\n\n        (1) Patients with a history of hypersensitivity to ingredients of ECARD LD&HD combination\n        tablets, thiazides, or their analogues (e.g. sulphonamide derivatives such as\n        chlortalidone) (2) Patients with anuria or patients under hemodialysis (3) Patients with\n        acute renal failure (4) Patients with noticeably decreased Na and K levels in body fluids\n        (5) Pregnant women or women planning to become pregnant\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Hypertension"
            }
        }, 
        "enrollment": {
            "#text": "3157", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016183", 
            "org_study_id": "220-011", 
            "secondary_id": "JapicCTI-132362"
        }, 
        "intervention": {
            "arm_group_label": "Candesartan cilexetil / hydrochlorothiazide", 
            "description": "Candesartan cilexetil / hydrochlorothiazide combination tablets", 
            "intervention_name": "Candesartan cilexetil / hydrochlorothiazide", 
            "intervention_type": "Drug", 
            "other_name": "ECARD\u00ae Combination Tablets LD&HD"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Candesartan cilexetil", 
                "Candesartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug Therapy", 
        "lastchanged_date": "December 14, 2013", 
        "number_of_groups": "1", 
        "official_title": "ECARD Combination Tablets LD&HD Special Drug Use Surveillance: Long-term Use (12 Months)", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The frequency of adverse drug reactions by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with the study drug are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016183"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Calculation of summary statistics for actual measured values and the  change from baseline in systolic/diastolic blood pressure.", 
            "measure": "Changes from baseline in blood pressure", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 12 months"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}